AAP
LXRX icon

Arax Advisory Partners’s Lexicon Pharmaceuticals LXRX Stock Holding History

Arax Advisory Partners’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98 Hold
41
– – ﹤0.01% 5139
2026
Q1 		$64 Hold
41
– – ﹤0.01% 3647
2025
Q4 		$47 Sell
41
-5,056
-99% -$6.95K ﹤0.01% 3927
2025
Q3 		$6.88K Buy
+5,097
New +$5.79K ﹤0.01% 2758
2024
Q4 		– Sell
-639
Closed -$1K – 2608
2024
Q3 		$1K Hold
639
– – ﹤0.01% 2257
2024
Q2 		$1.07K Buy
+639
New +$1.15K ﹤0.01% 2153

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Arax Advisory Partners's LXRX Position: Q2 2026 in Review

Arax Advisory Partners held its Lexicon Pharmaceuticals (LXRX) position steady in Q2 2026 at 41 shares worth $98. The position accounts for ﹤0.01% of the portfolio, ranked #5139.

Arax Advisory Partners first reported a position in LXRX in Q2 2024 and has held it in 6 quarters since. The position peaked at $6.88K in Q3 2025. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Arax Advisory Partners held 41 shares of Lexicon Pharmaceuticals worth $98 as of Q2 2026.
  • Arax Advisory Partners left its Lexicon Pharmaceuticals share count unchanged in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5139 holding.
  • Arax Advisory Partners first reported a position in Lexicon Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • Arax Advisory Partners's Lexicon Pharmaceuticals position peaked at $6.88K in Q3 2025.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.